Evidence from twin, family and adoption studies suggests that, ultimately, genetic
markers may represent the most important trait-like characteristics in the etiology
of major psychiatric disorders. However, genetic predisposition appears to vary
across patients and to "explain" no more than 25% to 60% of the observed phenotypic
variance, depending on the onset of illness, severity of illness, and long-term
course of clinical syndromes. Therefore, genetic predisposition has been conceptualized
as acting nonspecifically, by elevating a subject's "vulnerability" (or "sensitivity")
to environmental or endogenous challenges. Vulnerability, however, is neither necessary
nor sufficient for the development of psychiatric disorders.
A subject's vulnerability is typically compensated, at least in part, by resilience
factors. The term "resilience" is used here as a broader concept than just neurogenesis,
encompassing all those intrinsic/endogenous mechanisms that support and maintain health,
thereby enabling patients to cope with stressful situations (includes the concept of
autotherapeutic capacity). This may include personality traits supporting or impeding
social skills.
In our molecular-genetic study of 257 patients treated with antidepressants or
antipsychotics and genotyped for 178 candidate genes, we found correlations as
high as 0.5604 (p = 0.0000; nonimprovers included; c95 = [0.4123, 0.6797])
between the phenotype (onset of improvement) and the subjects' coordinate on the
first eigenvector of a configuration of 26 genomic loci (31% explained phenotypic
variance). Positive as well as negative correlations of the same order of
magnitude were detected, with the underlying configurations sharing "core" loci
while differing in their "accessory" loci, thus suggesting the existence of
mechanisms that can support or impede recovery. No single genomic locus seemed
to be either necessary or sufficient for having the phenotype, whereas significant
non-linear interactions between the genomic loci appeared to play a key role.
Interestingly, there was some overlap with genomic regions independently identified
as being linked to functional psychoses, again with subgroups displaying positive
or negative correlations between the configuration of genomic loci and the phenotype
(vulnerability to functional psychoses: affected/unaffected sib pairs).
Angst J., Scharfetter C, Stassen HH: Classification of Schizoaffective Patients by
Multidimensional Scaling and Cluster Analysis. Psychiatria Clin 1983; 16:
254-264
Angst J, Bänninger R, Nüsperli M, Scharfetter C, Stassen HH: Syndromale Gruppierungen endogener
Psychosen in genetischer Sicht. In: Perspektiven der Schizophrenie-Forschung, ed: Pflug B.,
Foerster K., Straube E.; Fischer, Stuttgart New York, 1985: 25-38
Stassen HH, Scharfetter C, Angst J: Morbid risks of subgroups of affective disorders: some
methodological and empirical results. J Psychiat Research 1987; 21: 347-355
Stassen HH, Scharfetter C, Winokur G, Angst J: Familial syndrome patterns in schizophrenia,
schizoaffective disorder, mania and depression. Eur Arch Psychiatr Neurol Sci 1988; 237:
115-123
Angst J, Stassen HH, Gross G, Huber G, Stone MH: Suicide in affective and schizoaffective
disorders. In: Marneros A. and Tsuang M.T. (eds) Affective and Schizoaffective disorders.
Springer, Berlin-Heidelberg 1990: 168-185
Stassen HH, Schmid GB, Gross G, Angst J, Huber G: Prädiktoren des langfristigen Verlaufs
schizophrener Erkrankungen. In: G. Huber (ed), Idiopathische Psychosen: Psychopathologie,
Neurologie, Therapie. Schattauer, Stuttgart-New York, 1990: 95-104
Scharfetter C, Stassen HH: Psychopathological concepts. Psychopathology 1995; 28: 8-12
Stassen HH, Ragaz M, Reich T: Age-of-onset or age-cohort changes in the lifetime occurrence of
depression? Psychiat Genetics 1997; 7: 27-34
Angst J, Stassen HH: Methodische Probleme der Prüfung von Antidepressiva. In: Stieglitz RD,
Fähndrich E, Möller HJ (eds): Syndromale Diagnostik psychischer Störungen. Hogrefe, Göttingen
1998: 5-12
Angst J, Angst F, Stassen HH: Suicide risk in patients with major depressive disorder. J Clin
Psychiatry 1999; 60,2: 57-62
Angst F, Stassen HH, Clayton PJ, Angst J: Mortality of patients with mood disorders: follow-up
over 34 to 38 years. J Aff Disorders 2002; 68: 167-181
Stassen HH: Veränderungen der Sprechmotorik. In: T.Jahn (ed) Bewegungsstörungen bei psychischen
Erkrankungen. Springer Heidelberg 2004: 107-125
Angst J, Sellaro R, Stassen HH, Gamma A: Diagnostic conversion from depression to bipolar
disorders: results of a long-term prospective study of hospital admissions. J Aff Disorders
2005; 84(2-3): 149-157
Stassen HH, Angst J, Scharfetter C, Szegedi A: Therapie mit Antidepressiva: Erfolg von
genetischen Faktoren abhängig? Leading Opinions, Neurologie & Psychiatrie 2005; 6: 25-27
Stassen HH, Scharfetter C: Ethnische Zugehörigkeit und Vulnerabilität am Beispiel der
Affektkrankheiten und Schizophrenien. Die Psychiatrie 2005; 2: 85-95
Stassen HH, Angst J, Scharfetter C: Genetik affektiver Störungen —der quantitative Ansatz
syndrom-orientierter Modelle. In: M. Leuzinger-Bohleber, S. Hau, H. Deserno (hsg): Depression
—Pluralismus in Praxis und Forschung, Vandenhoeck & Ruprecht, Göttingen, 2005, pp. 219-257
Stassen HH, Scharfetter C, Angst J: Functional Psychoses —Molecular-genetic Evidence for a
Continuum. In: A. Marneros and H.S. Akiskal (eds) The overlap of affective and schizophrenic
spectra. Cambridge University Press 2006; pp. 55-78
Stassen HH, Scharfetter C: Vulnerability, resilience and response to psychotropic drugs:
shared genetic factors? Am J Med Genetics 2006; 141: 707-708
Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A: Is there a common resilience mechanism
underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry
2007; 68(8): 1195-1205